Related Experiment Videos
Technology evaluation: FluMist, University of Michigan
1Novartis Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com
Current Opinion in Molecular Therapeutics
|March 16, 2001
Abstract:
FluMist is an intranasal influenza vaccine, which has been developed by Aviron. The genetically engineered, live, attenuated, cold-adapted virus vaccine produces influenza infection without the symptoms. The product has been field for approval in the US, where Merrill Lynch expects it to be marketed by mid-2000 [336561].